Adjuvant chemotherapy after radical prostatectomy in patients with stage III–IV prostate cancer without distant metastases
https://doi.org/10.17650/1726-9776-2017-13-4-79-84
Abstract
Objective is study on the clinical efficacy of the treatment method using polychemotherapy in the docetaxel + vinorelbine regimen in patients with prostate cancer of stage III–IV without distant metastases.
Materials and methods. The study included 112 patients, who underwent radical prostatectomy on prostatic adenocarcinoma in the period 2006–2010 at N.N. Alexandrov National Cancer Center of Belarus.
Results. The developed scheme of chemotherapy after radical prostatectomy showed its effectiveness in patients with the spread of a tumor characterized by the criterion pT3b–4pN0 or pT3apN0 with Gleason sum ≤7 and prostatic specific antigen level before operation >20 ng/ml. In patients with pT3aN0 tumor with a Gleason sum ≤7 and prostatic specific antigen level before surgery <20 ng/ml, adjuvant chemotherapy is not justified.About the Author
S. L. Polyakov
N.N. Alexandrov National Cancer Center of Belarus
Russian Federation
Russian Federation
Lesnoy, Minsk Region 223040
References
1. Океанов А.Е., Моисеев П.И., Левин Л.Ф. Статистика онкологических заболеваний в Республике Беларусь (2004–2013). Под ред. О.Г. Суконко. Минск: РНПЦ ОМР им. Н.Н. Александрова, 2014. С. 171–177. [Оkeanov А.Е., Моiseev P.I., Levin L.F. Statistics of oncologic diseases in the Republic of Belarus (2004–2013). Ed. О.G. Sukonkо. Мinsk: N.N. Alexandrov RNPTS OMP, 2014. Pp. 171–177 (In Russ.)].
2. Pettaway C.A., Pisters L.L., Troncoso P. et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 2000;18(5):1050–7. DOI: 10.1200/JCO.2000.18.5.1050. PMID: 10694556.
3. Clark P.E., Peereboom D.M., Dreicer R. et al. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 2001;57(2):281–5. PMID: 11182337.
4. Oh W.K., George D.J., Kaufman D.S., Moss K. et al. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin Oncol 2001;28(4 Suppl 15):40–4. PMID: 11685727.
5. Dreicer R., Klein E.A. Preliminary observations of singleagent docetaxel as neoadjuvant therapy for locally advanced prostate cancer. Semin Oncol 2001;28(4 Suppl 15):45–8. PMID: 11685728.
6. Boccon-Gibod L., Djavan W.B., Hammerer P. et al. Management of prostate specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract 2004;58(4):382–90. PMID: 15161124.
7. Moul J.W. Prostate specific antigen only progression of prostate cancer. J Urol 2000;163(6):1632–42. PMID: 10799151.
8. Kupelian P., Katcher J., Levin H. et al. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996;48(2):249–60. PMID: 8753737.
9. Grossfeld G.D., Latini D.M., Lubeck D.P. et al. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 2003;169(1): 157–63. DOI: 10.1097/01.ju.0000036470.57520.a0. PMID: 12478126.
10. Freedland S.J., Terris M.K., Csathy G.S. et al. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol 2004;171(6 Pt 1):2215–20. PMID: 15126788.
11. Демешко П.Д., Красный С.А. Биохимический рецидив рака предстательной железы после радикальной простатэктомии. Минск: Принтхаус, 2015. 160 с. [Demeshko P.D., Krasny S.A. Biochemical recurrence of prostate cancer after radical prostatectomy. Minsk: Printhouse, 2015. 160 p (In Russ.)].
12. Демешко П.Д. Сравнительный анализ отдаленных результатов радикальной простатэктомии и дистанционной лучевой терапии у пациентов, страдающих раком предстательной железы с высоким онкологическим риском. Онкоурология 2015;12(2):61–8. [Demeshko P.D. Radical prostatectomy versus external beam radiotherapy for high risk prostate cancer: comparison of treatment outcomes. Onkourologiya = Cancer Urology 2015;12(2):61–8 (In Russ.)]. DOI: 10.17650/1726-9776-2015-11-2-61-68.
Review
For citations:
Polyakov S.L. Adjuvant chemotherapy after radical prostatectomy in patients with stage III–IV prostate cancer without distant metastases. Cancer Urology. 2017;13(4):79-84. (In Russ.) https://doi.org/10.17650/1726-9776-2017-13-4-79-84
Views:
1053
Email this article 